V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220017107 | 220007400 | null | 108 | Palliative (P) | 2014-03-17 | 2014-03-17 | Hydroxycarbamide | N | N | 220028558 | HYDROXYCARBAMIDE |
| 220017108 | 220020864 | 1.68 | 74.7 | null | 2017-08-02 | 2017-10-21 | Cytarabine low (10to20mg/m2) IV/SC | N | N | 220028560 | CYTARABINE |
| 220017109 | 220014076 | null | 43 | Curative (C) | 2015-03-05 | 2015-03-05 | AML Downs HA | N | N | 220028566 | NOT MATCHED |
| 220017110 | 220014077 | 0 | 34.2 | Curative (C) | 2014-03-22 | 2014-03-27 | AML MyeChild 01 HD AraC | N | N | 220028571 | NOT MATCHED |
| 220017111 | 220007407 | null | 72.6 | Palliative (P) | 2013-11-18 | 2014-01-03 | ATG + Cyclophosphamide TBI Allo | N | N | 220028590 | NOT MATCHED |
| 220017112 | 220007409 | 0 | 6.9 | Curative (C) | null | 2016-01-24 | null | N | N | 220028601 | NOT MATCHED |
| 220017113 | 220014079 | 1.75 | 69.2 | Palliative (P) | 2014-09-30 | 2014-10-21 | AML Downs haM | 2 | N | 220028602 | NOT MATCHED |
| 220017114 | 220017678 | 1.6 | 85.5 | Palliative (P) | 2014-02-05 | 2014-02-11 | Hydroxycarbamide | N | N | 220028630 | HYDROXYCARBAMIDE |
| 220017115 | 220007413 | 0 | 46.2 | Palliative (P) | 2015-01-22 | 2015-12-20 | Hydroxycarbamide | N | N | 220028631 | HYDROXYCARBAMIDE |
| 220017116 | 220007414 | 1.04 | 37 | Curative (C) | 2013-08-12 | 2013-08-17 | AML MyeChild 01 A Mitozantrone/Cytarabine | null | null | 220028637 | NOT MATCHED |
| 220017117 | 220017679 | 1.81 | 83 | Curative (C) | 2017-01-21 | 2017-02-07 | Hydroxycarbamide | N | N | 220028644 | HYDROXYCARBAMIDE |
| 220017118 | 220014083 | 1.77 | 10.2 | Curative (C) | 2018-05-24 | 2018-06-29 | CYCLOPHOSPHAMIDE + CYTARABINE + ETOPOSIDE | null | N | 220028650 | NOT MATCHED |
| 220017119 | 220007416 | 1.7 | 76 | Curative (C) | 2016-11-23 | 2016-11-23 | null | 01 | N | 220028652 | NOT MATCHED |
| 220017120 | 220007417 | 1.78 | 25.55 | Palliative (P) | 2014-05-16 | 2014-05-16 | APML Consolidation II ATRA,Idarubicin | 2 | N | 220028662 | NOT MATCHED |
| 220017121 | 220007420 | 0 | 65.1 | Palliative (P) | 2015-08-22 | 2015-11-19 | Cytarabine Low Dose | 2 | N | 220028665 | CYTARABINE |
| 220017122 | 220007421 | 1.81 | 69.3 | Adjuvant (A) | 2018-01-22 | 2018-01-23 | Hydroxycarbamide | 2 | N | 220028665 | HYDROXYCARBAMIDE |
| 220017123 | 220017682 | null | null | Palliative (P) | 2016-07-01 | 2016-07-02 | Cytarabine Intrathecal (any age) | N | N | 220028677 | CYTARABINE |
| 220017124 | 220007424 | 0 | null | Palliative (P) | 2017-04-09 | 2017-04-09 | Hydroxycarbamide | 02 | N | 220028683 | HYDROXYCARBAMIDE |
| 220017125 | 220007424 | 0 | 45.7 | Palliative (P) | null | 2014-04-18 | Cytarabine Low Dose | N | N | 220028683 | CYTARABINE |
| 220017126 | 220014091 | 1.67 | 0 | Palliative (P) | 2016-10-18 | 2016-10-18 | Cytarabine Low Dose | N | N | 220028687 | CYTARABINE |
| 220017127 | 220014091 | null | 33.15 | null | 2015-08-10 | 2015-08-20 | AML MyeChild 01 HD AraC | null | N | 220028687 | NOT MATCHED |
| 220017128 | 220007428 | 1.53 | null | Palliative (P) | null | 2015-09-14 | Hydroxycarbamide | 99 | null | 220028704 | HYDROXYCARBAMIDE |
| 220017129 | 220017686 | 0 | 54 | Curative (C) | 2017-01-10 | 2017-04-25 | AML MyeChild 01 FLA | 02 | N | 220028706 | NOT MATCHED |
| 220017130 | 220007429 | 0 | 78 | Curative (C) | 2014-06-25 | 2014-07-14 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220028709 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017131 | 220007432 | 1.63 | 78.6 | Palliative (P) | 2015-08-23 | 2015-08-24 | Dasatinib | N | N | 220028709 | DASATINIB |
| 220017132 | 220007436 | 0 | 52.4 | Curative (C) | 2017-01-28 | 2017-01-28 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220028725 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017135 | 220021515 | 0 | 59.5 | null | 2015-03-25 | 2015-03-25 | Rituximab | null | N | 220028735 | RITUXIMAB |
| 220017136 | 220007438 | 1.77 | 95.5 | Curative (C) | 2017-09-25 | 2017-09-25 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220028743 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017137 | 220007439 | null | 61.1 | Curative (C) | 2018-01-16 | 2018-01-21 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | null | 220028760 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017138 | 220007441 | 0 | 58 | Curative (C) | 2017-07-07 | 2017-07-07 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | N | 220028763 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017139 | 220007444 | 1.7 | 76.5 | Disease modification (D) | 2014-12-22 | 2014-12-22 | Dasatinib | 02 | N | 220028768 | DASATINIB |
| 220017140 | 220007444 | 0 | 78 | Disease modification (D) | 2014-07-20 | 2014-07-20 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | N | 220028768 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017141 | 220007446 | 1.66 | 95.8 | Curative (C) | 2014-06-16 | 2014-06-20 | Dasatinib | 2 | N | 220028784 | DASATINIB |
| 220017143 | 220007449 | null | 84 | Disease modification (D) | 2018-03-18 | 2018-03-18 | Rituximab | null | N | 220028792 | RITUXIMAB |
| 220017144 | 220007451 | 1.55 | 82.2 | Disease modification (D) | 2018-02-04 | 2018-09-05 | Dasatinib | 2 | N | 220028797 | DASATINIB |
| 220017145 | 220007452 | 0 | null | Disease modification (D) | 2011-12-10 | 2013-02-22 | Dasatinib | 2 | N | 220028801 | DASATINIB |
| 220017146 | 220007455 | null | null | Not known (9) | 2013-09-12 | 2013-09-12 | Dasatinib | 02 | null | 220028803 | DASATINIB |
| 220017147 | 220007457 | 0 | 103.2 | null | 2018-02-23 | 2018-02-23 | Dasatinib | N | N | 220028807 | DASATINIB |
| 220017148 | 220007459 | 0 | 0 | Palliative (P) | 2018-01-01 | 2018-01-05 | Dasatinib | N | N | 220028812 | DASATINIB |
| 220017149 | 220007460 | 0 | null | Disease modification (D) | 2016-11-28 | 2016-11-28 | AML 18 TRIAL | 01 | null | 220028814 | AML18 TRIAL |
| 220017150 | 220007462 | null | null | Palliative (P) | 2015-02-12 | 2015-02-12 | Dasatinib | N | null | 220028823 | DASATINIB |
| 220017151 | 220014109 | null | 107.5 | Curative (C) | 2013-02-19 | 2013-03-11 | AML 18 TRIAL | Y | N | 220028829 | AML18 TRIAL |
| 220017152 | 220007464 | 1.63 | 65.2 | Disease modification (D) | 2015-05-06 | 2017-01-17 | Dasatinib | 02 | N | 220028832 | DASATINIB |
| 220017153 | 220007467 | null | 51.3 | Disease modification (D) | 2015-03-27 | 2015-03-27 | Dasatinib | N | N | 220028861 | DASATINIB |
| 220017154 | 220007469 | 0 | 78.6 | Adjuvant (A) | 2015-12-02 | 2015-12-02 | Dasatinib | 02 | N | 220028863 | DASATINIB |
| 220017155 | 220014112 | null | 54.7 | null | 2015-01-25 | 2015-03-23 | AML18 PILOT TRIAL | N | N | 220028868 | PILOT TRIAL |
| 220017156 | 220007474 | null | 75.4 | Curative (C) | 2016-12-10 | 2016-12-10 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | Y | 220028880 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220017157 | 220007477 | 1.58 | 77 | Disease modification (D) | 2016-01-13 | 2016-01-13 | Rituximab | 02 | null | 220028892 | RITUXIMAB |
| 220017158 | 220007481 | 1.93 | 8.9 | Disease modification (D) | 2016-12-01 | 2016-12-06 | Rituximab (Maintenance) | N | N | 220028899 | RITUXIMAB |
| 220017159 | 220007482 | null | 59.6 | Curative (C) | 2016-02-25 | 2016-02-27 | AML18 PILOT TRIAL | 2 | N | 220028901 | PILOT TRIAL |